Market Research Logo

The World Market for Diabetes Treatments

This Kalorama Information report , The World Market for Diabetes Treatments, provides market estimates and forecasts for the world market for diabetes treatments. The diabetes market is one of the fastest growing markets within the pharmaceutical sector, and is one of the few pharmaceutical sectors that are likely to continue to grow at double digit rates throughout the forecast period. Major contributing factors to growth are increasing obesity and an aging worldwide population. The total market for diabetes treatments is divided into two major segments:

  • Insulin Markets in US, Europe, Japan, ROW
  • Oral Hypoglycemics in US, Europe, Japan, ROW
For each of these market segments the report provides market share and regional breakout (US, Europe, Asia, ROW). The report also discusses treatment for diabetes complications and natural and herbal treatments.

The report’s geographic scope is worldwide with information for specific geographical regions; world demographics; life expectancy by country, and other general issues affecting the market. Trends covered in the report include:

  • New Products and the Development Pipeline (Afrezza, Bydureon, Syncria, AVE0010, Balaglitazone, Metgluna Otelixizumab and others)
  • Transplantation Research Efforts
  • Β-Cell Transplantation Research
  • Potential New Drug for Type 2 Diabetes
  • Insulin Pills
  • Three-month Insulin Shot
  • Outsourcing of Diabetes Projects
  • Reclassification of Cause of Death
Information is presented as a worldwide overview, with special emphasis on the U.S., Europe, and other key markets.

A market summary includes market analysis by product and region and a competitive analysis of leading providers. Additionally, key company profiles are included, including profiles of the following:

  • Amylin Pharmaceuticals
  • AstraZeneca
  • GlaxoSmithKline
  • Eli Lilly & Co.
  • Merck
  • Metabolex, Inc.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi-Aventis Group
  • Takeda Pharmaceutical Company Limited
The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information.

For the purpose of this study, Kalorama Information conducted interviews with more than 25 key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Additional interviews were completed with relevant company representatives including marketing directors, division managers, and product representatives.

All market data pertains to the world market at the manufacturers’ level. The base year for data was 2009. Historical data was provided for the years 2008, with forecast data provided for 2010 through 2015. Compound annual growth rates (CAGRs) are provided for 2008-2015 periods for each region and/or segment covered. Competitive analysis is provided for the year 2009. The forecasted market analysis for 2009-2015 was largely based on demographic trends, new developments, innovative technology and global expansion.


"Safe Bet" Diabetes Market Spurs Competition and New Products

The diabetes market is one of the fastest growing areas within the pharmaceutical sector, one of the few areas that is likely to continue to grow at double digit rates, according to healthcare market research publisher Kalorama Information. The promise of a near-certain market for patients has lead to competition among top names in pharmaceuticals to try to secure a position in the market with a new product, according to The World Market for Diabetes Treatments.

Diabetes is typically treated using diet control, exercise, and the monitoring of blood glucose several times a day. In some cases oral medication and/or insulin is prescribed, especially where diet or exercise is not enough, creating opportunity for drug makers. According to the report, the total diabetes therapeutic market reached $24.9 billion in 2009, increasing 16.4% from the previous year. This level of growth is expected to continue at least for the next two years, according to Kalorama Information. Major contributing factors to growth are increasing obesity and an aging worldwide population.

"Diabetes is seen as kind of a 'safe bet' development area as pharmacos try to carve out a piece of this income stream with a treatment that is a bit more effective," said Bruce Carlson, Publisher of Kalorama Information. "Unfortunately there has been little or no improvement in the numbers through diet and exercise. Even if there were improvement, there would still be a large pool of existing patients requiring treatment."

Top companies in the market include NovoNordisk, Sanofi-Aventis, GlaxoSmithKline, Merck and Takeda. Kalorama’s report lists over 100 new diabetes products in the development pipeline by these firms and others. While the entire market is considered safer for investment than other pharmaceutical markets, individual product success is never guaranteed; products will succeed or fail, depending on their effectiveness, marketing, and how well they fit with medical practice.

The report, The World Market for Diabetes Treatments, contains more information on epidemiology, products, companies operating in the market, forecasts and market estimates.

  • Executive Summary
    • BACKGROUND
    • SCOPE AND METHODOLOGY
    • SIZE AND GROWTH OF THE MARKET
      • Table Total Worldwide Diabetes Therapeutics Market Revenues 2008-2015
    • KEY ISSUES AND TRENDS AFFECTING MARKET
    • LEADING COMPETITORS
  • Introduction
    • BACKGROUND
      • Table Estimated Number of Preventable Diabetes Cases and Complications in the United States
    • THERAPEUTIC PRACTICES
      • France
      • Germany
      • Italy
      • Japan
      • Spain
      • United Kingdom
      • United States
      • China
      • India
    • CURRENT THERAPEUTICS FOR DIABETES
      • Insulin
      • Regular Insulin
      • Long-Acting and Basal Insulin
      • Rapidly Acting Insulin
      • Combinations
      • Insulin Pumps
      • Insulin Pens
      • Inhaled Insulin
      • Other Treatments
        • Table Key Insulin Products for the Treatment of Diabetes (Brand, Insulin Type, Manufacturer /Marketer)
      • Oral Hypoglycemics
      • Sulfonylureas
      • Biguanides
      • á-Glucosidase Inhibitors
      • Thiazolidinediones
      • Meglitinides
      • D-Phenylalanine Derivatives
      • GLP1 Agonists
      • DPP-IV Inhibitor
        • Table Key Oral Hypoglycemics for the Treatment of Type II Diabetes (Brand, Compound, Manufacturer/Marketer, and Class)
    • CURRENT THERAPEUTICS FOR DIABETIC COMPLICATIONS
      • Antihypertensive Therapy
      • ACE Inhibitors
        • Table Common ACE Inhibitors on the Market for Diabetic Hypertension (Brand, Compound, Manufacturer/Marketer)
      • á/â(Alpha/Beta)-Blockers
        • Table Common Adrenergic Receptors (á and â) on the Market for Diabetic Hypertension (Brand Name, Compound, Manufacturer/Marketer, Receptor Type)
      • Calcium Channel Blockers
        • Table Common Calcium Channel Blockers and Combinations on the Market for Diabetic Hypertension (Brand Name, Compound, Manufacturer/Marketer)
      • Diuretics
        • Table Common Diuretic Products and Diuretic Combinations on the Market for Diabetic Hypertension (Brand, Compound[s], Manufacturer/Marketer, Class)
      • Angiotensin II Receptor Antagonists
        • Table Common Angiotensin II Receptor Antagonists on the Market for Diabetic Hypertension ((Brand, Compound, Manufacturer/Marketer)
      • Dyslipidemia Therapy
      • HMG-CoA Reductase Inhibitors--Statins
      • Bile Acid Sequestrants
      • Fibric Acid Derivatives
      • Niacin
      • Cholesterol Absorption Inhibitors
        • Table Commonly Used Antilipemic Agents on the Market for Diabetic Dyslipidemia (Brand, Compound[s], Manufacturer/Marketer, Class)
      • Atherosclerosis Therapy
      • Arrhythmia Therapy
        • Table Vaughn Williams Classification of Anti-Arrhythmic Drugs Classification Drug Type Representative Drug Conditions Treated
        • Table Common Antiarrhythmatic Drugs (Brand, Compound, Manufacturer/Marketer, Group)
      • Peripheral Vascular Disease Therapy
        • Table Drugs Commonly Used to Combat Diabetic Peripheral Vascular Disease (Brand, Compound, Manufacturer/Marketer, Type)
  • Total Market Revenues, Forecast and Competitive Analysis
    • Table Total Worldwide Diabetes Therapeutics Market Revenues 2008-2015
    • Total Worldwide Diabetes Market Analysis by Geographic egment
      • Table Worldwide Diabetes Market Analysis by Region/Country, 2009
    • Total Worldwide Diabetes Market Competitive Analysis
      • Table Share of Total Worldwide Diabetes Therapeutics Market by Leading Supplier 2009
    • TOTAL WORLDWIDE DIABETES MARKET BY SEGMENT
      • Insulin
        • Table Total Worldwide Insulin Market Revenues 2008-2015
        • Table Worldwide Insulin Market Analysis by Region/Country, 2009
        • Table Share of Total Worldwide Insulin Market by Leading Supplier 2009
      • Oral Hypoglycemics
        • Table Total Worldwide Oral Hypoglycemics Market Revenues 2008-2015
        • Table Worldwide Oral Hypoglycemics Market Analysis by Region/Country, 2009
        • Table Share of Total Worldwide Oral Glycemics Market by Leading Supplier 2009
  • Key Issues, Trends and Developments
    • NEW PRODUCTS AND THE DEVELOPMENT PIPELINE
      • Table Recently Introduced or Diabetes-Designated Products (Product, Generic Name, Company, Diabetes Type, Introduction/Approval Date)
      • Table Products in Development for Diabetes
      • Afrezza
      • Bydureon
      • Syncria
      • AVE0010 Once Daily and Twice Daily
      • Balaglitazone
      • Dapagliflozin and Dapagliflozin/Meformin Fixed Dose Combination
      • Degludec and Degludec Plus
      • Daimyd Vaccine
      • Dutogliptin
      • Glinsuma, Glufast, Metgluna
      • MK 0431C
      • Ondero
      • Oral-lyn
      • Otelixizumab
      • Taspoglutide
    • TRANSPLANTATION RESEARCH EFFORTS
      • B-Cell Transplantation Research
    • POTENTIAL NEW DRUG FOR TYPE 2 DIABETES
    • INSULIN PILLS
    • THREE-MONTH INSULIN SHOT
    • OUTSOURCING OF DIABETES PROJECTS
    • RECLASSIFICATION OF CAUSE OF DEATH
  • Nutritional Supplement and Herbal Approaches to the Treatment of Diabetes
    • BACKGROUND
    • NUTRITIONAL SUPPLEMENTS
      • Ascorbic Acid (Vitamin C)
      • Biotin
      • Chromium
      • Copper
      • Magnesium
      • Niacin and Niacinamide
      • Potassium
      • Selenium
      • Thiamine
      • Vanadium
      • Vitamin B6 (Pyridoxine)
      • Vitamin B12
      • Vitamin E
      • Zinc
      • Nutritional Treatment of Diabetic Neuropathy
    • HERBAL TREATMENT OF DIABETES
      • Aloe (Various)
      • Arctium lappa (Burdock Root)
      • Allium cepa (Onion)
      • Grifola frondosa (Maitake Mushroom)
      • Mulberry
      • Panax ginseng (Korean ginseng)
    • AYURVEDIC MEDICINE AND HERBS
      • Gymnema sylvestre (Asclepias germinata)
      • Momordica charantia (Bitter Gourd)
      • Trigonella foenum graecum (Fenugreek)
    • OTHER HERBS WITH SIGNIFICANT ANTI-DIABETIC FFECTS
    • TRADITIONAL CHINESE MEDICINE
  • Conclusions and Strategic Implications
    • FIRST CONCLUSION
      • Implications
    • SECOND CONCLUSION
      • Implications
    • THIRD CONCLUSION
      • Implications
    • FOURTH CONCLUSION
      • Implications
    • FIFTH CONCLUSION
      • Implications
    • SIXTH CONCLUSION
      • Implications
    • SEVENTH CONCLUSION
      • Implications
    • EIGHTH CONCLUSION
      • Implications
    • NINTH CONCLUSION
      • Implications
    • TENTH CONCLUSION
      • Implications
    • ELEVENTH CONCLUSION
      • Implications
    • TWELFTH CONCLUSION
      • Implications
    • THIRTEENTH CONCLUSION
      • Implications
    • FOURTEENTH CONCLUSION
      • Implications
    • FIFTEENTH CONCLUSION
      • Implications
  • Leading Manufacturers
    • OVERVIEW
    • AMYLIN PHARMACEUTICALS
    • ASTRAZENECA
    • GLAXOSMITHKLINE
    • ELI LILLY & CO.
    • MERCK
    • METABOLEX, INC.
    • NOVO NORDISK A/S
    • PFIZER INC.
    • SANOFI-AVENTIS GROUP
    • TAKEDA PHARMACEUTICAL COMPANY LIMITED
  • Glossary
  • Company Directory

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report